Towards National Health Technology Assessment for Medicines in South Africa: Data Requirements and Status of Health-related Quality of Life Research
Year: 2021
Type: article
Study design: Systematic Review
Abstract: Background: Health technology assessment (HTA) will be used in decisions on the availability and funding of medicines in South Africa under National Health Insurance (NHI). Health-related quality of life (HRQoL) data is a key HTA element because it is used in the clinical assessment of the medicine being introduced and is integral to the economic evaluation thereof when a cost-utility analysis (CUA) is conducted. Consequently, a lack of robust HRQoL data may delay or prevent patients from accessing new medicines when NHI is introduced. Aim: To make recommendations for evidence generation activities supportive of national HTA in the public health sector, focussing on the South African HRQoL data generated for CUA, and the organisations conducting such research. Methods: The study had two components. The first was a review of the requirements in the South African Guideline for Pharmacoeconomic Submissions (SAGPS), comparing it against similar guidelines from Africa and England using an established HTA framework. The second was a systematic review of HRQoL research conducted in South Africa which formed the basis for three distinct analyses. The first analysis quantified and evaluated the HRQoL studies for its suitability for CUA. The second, a bibliometric analysis, determined the performance indicators of the research output and identified the collaborative networks. The third critiqued the translation methodology of the HRQoL instruments identified in the review that had been modified for use in South Africa. Results: The SAGPS generally reflects the evidence requirements for a comprehensive HTA and is, therefore, suitable for national HTA of medicines. However, most HRQoL data from existing studies are unlikely to support a CUA because it is observational, cross-sectional and lacks reporting on the methodological details necessary to determine the study’s scientific merit according to HTA requirements. And despite South African based-researchers and organisations’ strong contribution to this research area, their performance was below that of their international counterparts. Overall, there was a lack of research continuity, with numerous isolated research networks. Finally, several HRQoL instruments suitable for iii a CUA were identified, but few would meet the SAGPS requirements for being valid within the South African context. Recommendations: Researchers and pharmaceutical manufacturers should familiarise themselves with the SAGPS’ content and generate scientifically robust data meeting the requirements therein. South African HRQoL research output could be optimised for use in a CUA by better study design and researchers expanding their local and international networks to those working in HTA and related fields. The EQ- 5D 3-levels is best suited for use in South Africa where data are needed for a CUA, and therefore its use should be encouraged and supported through establishing a South African value set. Conclusions: HTA stakeholders and participants should acquaint themselves with the data requirements outlined in the SAGPS as it is indicative of a comprehensive HTA and could form the basis of national HTA under NHI. Additionally, future data generation activities should incorporate the recommendations from this study because existing South African HRQoL data are unlikely to support a CUA as part of HTA.
Author: Marsh, S
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: green
Funder: Medical Research Council
OpenAlex ID: W7220820633
